SCHEMBL4373848

SCHEMBL4373848

O=C1Nc2ccc(-c3ccc(Cl)cc3)cc2C1=NO

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.49
LRRK2 Q5S007 3/20 0.48
MAOA P21397 2/20 0.46
MAOB P27338 2/20 0.46
TGM2 P21980 1/20 0.46
CES1 P23141 1/20 0.46
GALR3 O60755 1/20 0.46
IDO1 P14902 1/20 0.46
JAK2 O60674 1/20 0.44
NTRK1 P04629 1/20 0.44
MET P08581 1/20 0.44
FGFR1 P11362 1/20 0.44
PRKACA P17612 1/20 0.44
MAP2K2 P36507 1/20 0.44
FLT3 P36888 1/20 0.44
GSK3B P49841 1/20 0.44
MAP2K1 Q02750 1/20 0.44
MST1R Q04912 1/20 0.44
NTRK3 Q16288 1/20 0.44
NTRK2 Q16620 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11260371 0.84 PDE3B (0.66) LRRK2MAOAMAOBJAK2PRKACA
Hydrochloric Acid SCHEMBL11260369 0.82 PDE3B (0.64) LRRK2MAOAMAOBJAK2PRKACA
Hydrochloric Acid SCHEMBL11260364 0.82 PDE3B (0.64) LRRK2MAOAMAOBJAK2PRKACA
Hydrochloric Acid SCHEMBL11192803 0.81 PDE3B (0.62) LRRK2MAOAMAOBJAK2PRKACA
SCHEMBL4370977 0.79 CES1 (0.73) KDRMAOAMAOBTGM2CES1
SCHEMBL30813240 0.74 LRRK2 (0.60) KDRLRRK2FLT3CA1CA2
SCHEMBL6315587 0.74 TGM2 (0.61) LRRK2TGM2CES1CA1CA2
SCHEMBL6325243 0.74 MAPT (0.60) LRRK2CA1CA2
SCHEMBL7220775 0.74 SMN1; SMN2 (0.40) KDRLRRK2IDO1CA1CA2
SCHEMBL6322987 0.74 TGM2 (0.61) LRRK2TGM2CES1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595336-B2 Isatine derivatives with neurotrophic activity NEUROSEARCH A/S (DK) 2009-09-29 US disclosed
US-7282511-B2 Isatine derivatives with neurotrophic activity NEUROSEARCH A/S (DK) 2007-10-16 US disclosed
EP-1736468-A2 Isatin derivatives with neurotrophic activity useful in the treatment of diseases mediated by the nerve growth factor (NGF) activation NeuroSearch A/S (DK) 2006-12-27 EP disclosed
US-20060229311-A1 Isatine derivatives with neurotrophic activity GROENBORG METTE 2006-10-12 US disclosed
US-20030040518-A1 Isatine derivatives with neurotrophic activity ANIONA APS (DK) 2003-02-27 US disclosed
EP-1255734-A1 ISATINE DERIVATIVES WITH NEUROTROPHIC ACTIVITY NeuroSearch A/S (DK) 2002-11-13 EP disclosed
WO-2001055110-A1 ISATINE DERIVATIVES WITH NEUROTROPHIC ACTIVITY NEUROSEARCH A/S (DK) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229311-A1 Isatine derivatives with neurotrophic activity BDNF, NTRK2, NGF KDR 3233/4885LRRK2 201/4885MAOA 620/4885
US-20030040518-A1 Isatine derivatives with neurotrophic activity BDNF, NTRK2, NGF KDR 3233/4885LRRK2 201/4885MAOA 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.